Knowledge Library

Bone metastasis platform to evaluate prophylaxis and treatment

Resource Type: Presentation
Resource Topic: Oncology & Immuno-oncology

VIEW

Immuno-Oncology Platform to Enable Discovery from Target to Drug

Resource Type: Webinar
Resource Topic: Oncology & Immuno-oncology

VIEW

CRISPR library screens identify frequent cancer mutations regulating PD-1 blockade response

AACR Annual meeting 2021 Wenrong Zhou1,* , Min Long2,3* , Tianyu Song3,* , Qiangqiang Fan1 , Zhengang Peng1 , Yong Cang3 , Qunsheng Ji1  1 Oncology and Immunology Unit, Research Service Division, WuXi AppTec (Shanghai) Co., Ltd., China; 2 Life Sciences Institute, Zhejiang University, Hangzhou, China; School of Life Science and Technology, ShanghaiTech University, Shanghai, …Read More >

Resource Type: Poster
Resource Topic: CRISPR/Cas9 Oncology & Immuno-oncology

VIEW

Engineered cell line panel complemented with in vivo models to enable next-generation target therapy discovery in cancer

 AACR Annual meeting 2021   Authors: Zhixiang Zhang1, Feifei Fan2, Xiaohe Shi2, Xiangyang Zuo2, Qingyang Gu2, Qunsheng Ji1. 1 WuXi AppTec, Shanghai, China; 2 WuXi AppTec, Jiangsu, China Corresponding Author: Qunsheng Ji. Email: ji_qunsheng@wuxiapptec.com   Background  Many cancer types are driven by specific gene aberrances, like gene fusions, mutations and copy number changes. It has led to …Read More >

Resource Type: Poster
Resource Topic: Oncology & Immuno-oncology

VIEW

Establishment of drug induced resistant tumor models enable the development of next generation anticancer therapeutics

AACR Annual meeting 2021  Ting Ni, Zhixiang Zhang, Xuzhen Tang, Hui Qi, Jingying Zhang, Ke Mao, Wenting Shi, Qingyang Gu, Qunsheng Ji WuXi AppTec, Suzhou, China  Abstract Recent advances in cancer biology and diagnosis are providing more targeted approaches to treat cancers. Therapy targeting the specific oncogenic driver could inhibit tumor progression and helps to …Read More >

Resource Type: Poster
Resource Topic: Oncology & Immuno-oncology

VIEW

Drug Hunter: Discovering New Frontiers in Cancer Treatments & Beyond

INNOVATION THAT MATTERS By Rich Soll, Senior Advisor, Strategic Initiatives at WuXi AppTec (@richsollwx) As a self-proclaimed drug hunter, Phil Jones is on a mission to identify the next generation of cancer medicines that improve the lives of patients with cancer. He leads a multi-disciplinary team of scientists at The University of Texas MD Anderson Cancer Center’s Institute …Read More >

Resource Type: Latest Science
Resource Topic: Cancer Research Oncology & Immuno-oncology

VIEW

Translational Oncology

Biomarker discovery Mouse clinical trial 61 PDX-derived primary cancer cell lines Drug-resistant xenograft models Combination therapy platform including radiation World leading genome sequencing and bioinformatics capability

Resource Type: Brochure
Resource Topic: Oncology & Immuno-oncology

VIEW

Immuno-Oncology Services

Immuno-oncology Platform An outstanding platform to enable cancer immunotherapy with one stop service: Immunological function assessment TIL analysis – Flowcytometry, Multiplex IF and Cytex Animal models – Syngeneic and humanized models Immune profiling by NGS – Single Cell RNAseq, Mutation burden and TCR/BCR repertoire Clinical biomarker services – CAP certification and GCP compliance

Resource Type: Brochure
Resource Topic: Oncology & Immuno-oncology

VIEW

WuXi Oncology and Immuno-Oncology Services

Integrated Oncology and Immuno-oncology Platform to Enable Translational Science from Drug Discovery to Clinical Biomarker CRISPR/Cas9 Gene Editing In Vitro Assay and HTS Tumor models Tumor Cell Panel and Screening Immunology and Immuno-oncology Platform Clinical Biomarker

Resource Type: Brochure
Resource Topic: Oncology & Immuno-oncology

VIEW